Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FIRE & FLOWER ANNOUNCES CANNABIS DISTRIBUTION AGREEMENT WITH MANITOBA LIQUOR & LOTTERIES
APRIL, 14, 2022
https://investors.fireandflower.com/news/news-details/2022/Fire--Flower-Announces-Cannabis-Distribution-Agreement-with-Manitoba-Liquor--Lotteries/default.aspx
Open Fields Distribution expands into Manitoba market by providing cross docking services and leveraging significant logistics experience with Pineapple Express Delivery
TORONTO, April 14, 2022 /CNW/ - Fire & Flower Holdings Corp. ("Fire & Flower" or the "Company") (TSX: FAF)(OTCQX: FFLWF), a leading cannabis consumer technology and retail platform, today announced that its wholly-owned subsidiary, Open Fields Distribution ("Open Fields") has entered into a one-year cannabis distribution agreement (the "Agreement") with Manitoba Liquor & Lotteries ("MBLL"). Under the Agreement, Open Fields will offer distribution of recreational cannabis products from licensed producers to retailers in the province of Manitoba at the direction of the MBLL.
Fire & Flower (CNW Group/Fire & Flower Holdings Corp.)
Strategic Benefits of the Agreement
* Extends the existing Open Fields business, which offers wholesale and distribution services in Saskatchewan, into a second province.
* Leverages significant experience of the Company's recently acquired logistics and delivery subsidiary, Pineapple Express Delivery.
* Enables retailers across Manitoba to receive product more efficiently and benefit from the established high level of service offered by Open Fields.
* Further enhances strategic relationships with key licensed producers across all segments of the Fire & Flower business.
"Open Fields was selected as part of a competitive RFP process to provide cross docking services in the province of Manitoba and we are delighted that MBLL has trusted our business to provide these services. Open Fields and Pineapple Express Delivery have significant experience in servicing retail customers in the provinces of Saskatchewan and Ontario and extending these services into an additional province creates scale and efficiency for the wholesale business segment," shared Trevor Fencott, Chief Executive Officer of Fire & Flower. "We will look to continue to pursue business opportunities and acquisitions that drive additional revenue by adding value to existing business segments."
About Fire & Flower
Fire & Flower is a leading, technology-powered, adult-use cannabis retailer with more than 100 corporate-owned stores in its network. The Company leverages its wholly-owned technology development subsidiary, Hifyre, to continually advance its proprietary retail operations model while also providing additional independent high-margin revenue streams. Fire & Flower guides consumers through the complex world of cannabis through education-focused, best-in-class retailing while the Hifyre digital retail and analytics platform empowers retailers to optimize their connections with consumers. The Company's leadership team combines extensive experience in the technology, cannabis and retail industries.
Through the strategic investment of Alimentation Couche-Tard Inc. (owner of Circle K convenience stores), the Company has set its sights on global expansion as new cannabis markets emerge and is poised to expand into the United States when permitted through its strategic licensing agreement with Fire & Flower U.S. Holdings upon the occurrence of certain changes to the cannabis regulatory regime.
Fire & Flower is a multi-banner cannabis retail operator that owns and operates the Fire & Flower, Friendly Stranger, Happy Dayz and Hotbox brands. Fire & Flower Holdings Corp. owns all issued and outstanding shares in Fire & Flower Inc. and Friendly Stranger Holdings Corp., licensed cannabis retailers that own and operate cannabis retail stores in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and the Yukon territory.
To learn more about Fire & Flower, visit www.fireandflower.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws ("forward-looking statements"). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "project" and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions "may" or "will" occur. These statements are only predictions.
Forward-looking statements are based on the opinions and estimates of management of Fire & Flower at the date the statements are made based on information then available to the Fire & Flower. Various factors and assumptions are applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Forward-looking statements are subject to and involve a number of known and unknown, variables, risks and uncertainties, many of which are beyond the control of Fire & Flower, which may cause Fire & Flower's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such factors, among other things, include: regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; the impact of the COVID-19 pandemic; the ability of the Company to successfully achieve its business objectives and political and social uncertainties.
No assurance can be given that the expectations reflected in forward-looking statements will prove to be correct. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated April 30, 2021 and the heading "Risks and Uncertainties" in the management discussion and analysis for the quarter ended October 30, 2021 filed on its issuer profile on SEDAR at www.sedar.com . The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
SOURCE Fire & Flower Holdings Corp.
I would like to see this happen...
The public and The Street have totally lost confidence in the House and Senate reconciling cannabis legalization or even passing the SAFE Banking and MOORE Acts.
In the event they do get it done, you will want to widely own cannabis stocks because they will roar, even the Canadian cannabis companies, especially those with a USA foothold.
HEXO is a piece of S _ _ t company. Perhaps The Street isn't giving much credence to Simon gobbling up another bankruptcy candidate as he did when he saved Tilray from their creditors.
Kinder Morgan Announces First Quarter ‘22 Earnings Webcast
04/13/2022
HOUSTON--(BUSINESS WIRE)-- Kinder Morgan, Inc. (NYSE: KMI) today announced it will release first quarter 2022 earnings results on Wednesday, April 20, 2022 after market close and will hold a live webcast and conference call.
What: Kinder Morgan First Quarter ‘22 Earnings Results Webcast
When: April 20, 2022, at 3:30 p.m. CT, 4:30 p.m. ET
Where: http://ir.kindermorgan.com/presentations-webcasts
How: Live over the Internet by logging on to the web at the above address, or by phone (listen-only) by dialing 1-517-308-9185 and entering the passcode 4057642.
If you are unable to listen during the live webcast, the call will be archived at www.kindermorgan.com. A recording of the conference call will also be available for replay one hour after the call until the end of the day on May 20, 2022. To access the replay, please dial 1-203-369-0194 and enter passcode 63871.
About Kinder Morgan, Inc.
Kinder Morgan, Inc. (NYSE: KMI) is one of the largest energy infrastructure companies in North America. Access to reliable, affordable energy is a critical component for improving lives around the world. We are committed to providing energy transportation and storage services in a safe, efficient, and environmentally responsible manner for the benefit of people, communities and businesses we serve. We own an interest in or operate approximately 83,000 miles of pipelines and 141 terminals. Our pipelines transport natural gas, renewable fuels, refined petroleum products, crude oil, condensate, CO2 and other products, and our terminals store and handle various commodities including gasoline, diesel fuel, chemicals, ethanol, metals and petroleum coke. Learn more about our renewables initiatives on the low carbon solutions page at www.kindermorgan.com.
Media Relations
Dave Conover
newsroom@kindermorgan.com
Investor Relations
(713) 369-9490
km_ir@kindermorgan.com
www.kindermorgan.com
Source: Kinder Morgan, Inc.
Trulieve Opening Medical Marijuana Dispensary in Fort Myers, Florida
April 13, 2022 at 7:42 AM EDT
https://investors.trulieve.com/news-releases/news-release-details/trulieve-opening-medical-marijuana-dispensary-fort-myers-florida
New dispensary expands patient access beginning April 13; grand opening specials available
TALLAHASSEE, Fla., April 13, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) "Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the opening of a new medical cannabis dispensary in Fort Myers, Florida. Located at 15620 Summerlin Rd., the doors will open at 9 a.m. on Wednesday, April 13, 2022.
Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)
Grand opening festivities throughout the day at the new dispensary will include numerous partner giveaways, music, food trucks, deals and specials, and all registered patients will receive a 25% discount. Trulieve also offers statewide home delivery, convenient online ordering and in-store pickup.
"Trulieve is excited to expand access to medical cannabis in the Fort Myers market and build strong relationships in the community," said Kim Rivers, CEO of Trulieve. "Our company is driven by our commitment to providing tailored, high-quality patient care in a safe and comfortable environment."
As the state's leading medical cannabis provider, Trulieve's retail employees are trained to provide personalized patient care and support individuals at every stage of their cannabis journey. Trulieve dispensaries throughout Florida offer on-site consultations to help patients obtain appropriate medical products and dosages to ensure optimal cannabis experiences.
Trulieve patients across Florida can choose from the largest selection of THC and CBD products available in a variety of consumption methods, including smokable flower, concentrates, edibles, capsules, syringes, tinctures, topical creams, vaporizers, and more. Patients have access to nationally-beloved brands such as Bellamy Brothers, Bhang, Binske, Blue River, Black Tuna, Love's Oven, O.pen, and Sunshine Cannabis, all available exclusively at Trulieve in Florida.
For more information about additional Trulieve dispensary locations in Florida, how to become a registered patient, store activations and promotions, please visit www.trulieve.com/dispensaries/florida.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve
Investor Contact
Christine Hersey, Executive Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Rob Kremer, Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-opening-medical-marijuana-dispensary-in-fort-myers-florida-301524351.html
SOURCE Trulieve Cannabis Corp.
Cresco Labs Brings Its FloraCal Farms Brand to Illinois
April 13, 2022
https://investors.crescolabs.com/investors/press-releases/press-release-details/2022/Cresco-Labs-Brings-Its-FloraCal-Farms-Brand-to-Illinois/default.aspx
The premium craft brand arrives with flower, vapes and concentrates available for purchase ahead of 420
CHICAGO--(BUSINESS WIRE)-- Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced the launch of its premium craft brand FloraCal Farms, which features unique genetics in curated flower, live rosin vape and live rosin concentrate formats now available at all Illinois Sunnyside stores and other retailers ahead of the 420 cannabis holiday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005236/en/
Cresco Labs’s premium craft brand FloraCal Farms expands to Illinois with novel, exclusive genetics and flower, vape and concentrates formats. (Photo: Business Wire)
Cresco Labs’s premium craft brand FloraCal Farms expands to Illinois with novel, exclusive genetics and flower, vape and concentrates formats. (Photo: Business Wire)
“FloraCal Farms’ vision is to deliver a first-class experience to sophisticated cannabis consumers who value unique terpene profiles, flower structure and all the fruits of artisanal cultivation and processing methods,” said Charles Bachtell, CEO & Co-Founder of Cresco Labs. “We plan to launch FloraCal Farms in other markets throughout the year to reach the ultra-premium shopper. Along with our Cresco and High Supply brands, our uniquely designed portfolio architecture of tiered inhalable offerings and pricing will allow us to offer a variety of value propositions for consumers and to compete incredibly well in the marketplace.”
Born in Sonoma County, FloraCal Farms continues to honor its California heritage through a commitment to tailored craftsmanship established by wife-and-husband founders Karen and Drew Duval, who oversee commercial sales and cultivation at the Company. FloraCal Farms maintains a rigorous pheno-hunting process that starts with hundreds of plants, then hand-selects only the winning strains to be developed into flower, vapes and hand-crafted concentrates. Flower is always hand-harvested, trimmed and packaged to preserve delicate flower characteristics. Live rosin vapes and concentrates follow solventless extraction processes, an innovative method new to Cresco Labs’ wholesale portfolio that removes the oil containing components from the raw materials simply through ice water and manual agitation – without the use of chemical solvents. The resulting materials are pressed to produce live rosin bursting with the terpenes, flavor and potency that cannabis connoisseurs enjoy.
Available for sale forms at launch in Illinois include hand-trimmed flower (3.5g), live rosin vape cartridges (500mg) and live rosin badder concentrates (1g). More products and exclusive strains will arrive on dispensary shelves throughout the year.
The launch of FloraCal Farms in Illinois rounds out the Company’s wholesale portfolio in Illinois. Other available brands include Cresco, High Supply, Good News, Mindy’s, Wonder Wellness and Remedi.
For more information about FloraCal Farms, visit www.floracalfarms.com. To learn more about Cresco Labs, visit www.crescolabs.com.
About Cresco Labs Inc.
Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.
Facebook: Cresco Labs
Instagram: Cresco Labs
Twitter: Cresco Labs
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005236/en/
Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com
Investors:
Megan Kulick, Cresco Labs
Senior Vice President, Investor Relations
investors@crescolabs.com
For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com
Source: Cresco Labs Inc.
FIRE & FLOWER OBTAINS DTC ELIGIBILITY FOR ITS COMMON SHARES
APRIL, 13, 2022
https://investors.fireandflower.com/news/news-details/2022/Fire--Flower-Obtains-DTC-Eligibility-for-its-Common-Shares/default.aspx
TORONTO, April 13, 2022 /CNW/ - Fire & Flower Holdings Corp. ("Fire & Flower" or the "Company") (TSX: FAF) (OTCQX: FFLWF), a leading cannabis consumer technology and retail platform today announced that its common shares are now eligible for electronic clearing and settlement in the United States through the Depositary Trust Company ("DTC"). DTC is a subsidiary of the Depository Trust and Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies.
Fire & Flower logo (CNW Group/Fire & Flower Holdings Corp.)
"DTC Eligibility will make Fire & Flower's common shares more accessible to investors in the United States and help increase trading volumes. It is also an important step in connection with our proposed listing on the Nasdaq Capital Market, which we expect to be completed over the coming weeks," shared Trevor Fencott, Chief Executive Officer of Fire & Flower.
About Fire & Flower
Fire & Flower is a leading, technology-powered, adult-use cannabis retailer with more than 100 corporate-owned stores in its network. The Company leverages its wholly-owned technology development subsidiary, Hifyre, to continually advance its proprietary retail operations model while also providing additional independent high-margin revenue streams. Fire & Flower guides consumers through the complex world of cannabis through education-focused, best-in-class retailing while the Hifyre digital retail and analytics platform empowers retailers to optimize their connections with consumers. The Company's leadership team combines extensive experience in the technology, cannabis and retail industries.
Through the strategic investment of Alimentation Couche-Tard Inc. (owner of Circle K convenience stores), the Company has set its sights on global expansion as new cannabis markets emerge and is poised to expand into the United States when permitted through its strategic licensing agreement with Fire & Flower U.S. Holdings upon the occurrence of certain changes to the cannabis regulatory regime.
Fire & Flower is a multi-banner cannabis retail operator that owns and operates the Fire & Flower, Friendly Stranger, Happy Dayz and Hotbox brands. Fire & Flower Holdings Corp. owns all issued and outstanding shares in Fire & Flower Inc. and Friendly Stranger Holdings Corp., licensed cannabis retailers that own and operate cannabis retail stores in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and the Yukon territory.
To learn more about Fire & Flower, visit www.fireandflower.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws ("forward-looking statements"). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "project" and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions "may" or "will" occur. These statements are only predictions.
Forward-looking statements are based on the opinions and estimates of management of Fire & Flower at the date the statements are made based on information then available to the Fire & Flower. Various factors and assumptions are applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Forward-looking statements are subject to and involve a number of known and unknown, variables, risks and uncertainties, many of which are beyond the control of Fire & Flower, which may cause Fire & Flower's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such factors, among other things, include: regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; the impact of the COVID-19 pandemic; the ability of the Company to successfully achieve its business objectives and political and social uncertainties.
No assurance can be given that the expectations reflected in forward-looking statements will prove to be correct. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated April 30, 2021 and the heading "Risks and Uncertainties" in the management discussion and analysis for the quarter ended October 30, 2021 filed on its issuer profile on SEDAR at www.sedar.com . The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
SOURCE Fire & Flower Holdings Corp.
I still expect nothing to move the PPS upward. USA legalization is the only thing that will push us upward.
Stinky Greens Organic Platinum Jelly Now Available in Ontario
https://manage.kmail-lists.com/subscriptions/web-view?a=P6GTmJ&c=LwKGhr&k=254c5adc42de1ba07014969916d17438&m=TnWm3p&r=KFZQQBk
They are suffocating--->>>Aleafia Health Provides Further Update on its Convertible Debt
Holders representing approximately 62% of total Debentures extend Forbearance Period until April 26, 2022 to allow negotiations to continue
TORONTO – April 11, 2022 – Aleafia Health Inc. (TSX: AH, AH.DB, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is providing a corporate update regarding its outstanding listed unsecured convertible debentures (TSX: AH.DB), issued on June 27, 2019 and maturing on June 27, 2022 (the “Convertible Debt”).
Further to the Company’s announcements on February 1, and March 1, 16, and 31, 2022, the Forbearance Agreement, entered into between the Company and holders of Convertible Debt representing approximately 62% of the aggregate principal amount of debentures outstanding, has been extended until April 26, 2022. The Agreement automatically renews for 14-day periods thereafter unless advance notice to the contrary is provided.
The parties continue to work expeditiously and in good faith to negotiate a potential transaction to amend the terms associated with the Convertible Debt. While there can be no assurances regarding any outcome, the Company believes progress is being made towards a solution that is beneficial to its stakeholders.
For Investor & Media Relations:
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health, a vertically integrated and federally licensed Canadian cannabis company, owns three licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history, and operates a strategically located distribution centre, all in the province of Ontario. The Company produces a diverse portfolio of cannabis derivative products including oils, capsules, edibles, sublingual strips, and vapes, for sale in Canada in the adult-use and medical markets and is pursuing opportunities in select international jurisdictions. The Company owns and operates a virtual network of medical cannabis clinics staffed by physicians and nurse practitioners.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Let's hope tomorrow's news is better than the dilution news--->>>THE VALENS COMPANY TO HOLD CONFERENCE CALL TO DISCUSS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2022
Kelowna, B.C., April 7, 2022 – The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS) (the “Company” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, is pleased to announce it will issue its first quarter 2022 financial results for the period ended February 28, 2022, on Wednesday, April 13, 2022, after market close.
CONFERENCE CALL DETAILS
The Company will host a conference call the following day, Thursday, April 14, 2022, at 11:00 AM Eastern Time / 8:00 AM Pacific Time to discuss the financial results and business outlook.
Participant Dial-In Numbers:
Toll-Free: 1-877-407-0792
Toll / International: 1-201-689-8263
*Participants should request The Valens Company Earnings Call or provide confirmation code 13728569.
The call will be available via webcast on the Valens investor page of the Company website at https://thevalenscompany.com/investors/ or at this link. Please visit the website at least 15 minutes prior to the call to register, download, and install any necessary audio software. A replay of the call will be available on the Valens investor page approximately two hours after the conference call has ended.
Tyler Robson, Chief Executive Officer, Sunil Gandhi, Chief Financial Officer, Jeffrey Fallows, President, and Everett Knight, Executive Vice President of Corporate Development and Capital Markets, will be conducting a question-and-answer session following the prepared remarks.
ABOUT THE VALENS COMPANY
The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Valens Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and product development and custom manufacturing. Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next-generation products in development for future release. Finally, The Valens Company’s wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. For more information, please visit https://thevalenscompany.com. The Valens Company’s investor deck can be found specifically at https://thevalenscompany.com/investors/.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Jeff Fallows
The Valens Company
Investor Relations
ir@thevalenscompany.com
1 647.956.8254
KCSA Strategic Communications
Phil Carlson / Elizabeth Barker
VLNS@kcsa.com
1 212.896.1233 / 1 212.896.1203
Media
KCSA Strategic Communications
Anne Donohoe
adonohoe@kcsa.com
1 212.896.1265
NOTICE REGARDING FORWARD LOOKING STATEMENTS
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, economic conditions and anticipated courses of action.
The risks and uncertainties that may affect forward-looking statements include, among others, regulatory risk, United States border crossing and travel bans, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, reliance on a single facility, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
Thoughts in blue: Tilray Brands Announces Definitive Agreement With Hexo Corp. Related to Hexo’s Senior Secured Convertible Note
Best part of this news is GTI is rebranding their acquisitions to RISE. Please do it with all of the stores. Thanks for the heads-up GE_Jim.
Green Thumb to Open RISE Mankato, Its 77th Retail Location in the Nation, on April 14
APRIL 11, 2022
https://investors.gtigrows.com/investors/news-and-events/press-releases/press-release-details/2022/Green-Thumb-to-Open-RISE-Mankato-Its-77th-Retail-Location-in-the-Nation-on-April-14/default.aspx
CHICAGO and VANCOUVER, British Columbia, April 11, 2022 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE dispensaries, today announced it will open RISE Mankato on April 14. Profits from the first day of sales will be donated to Habitat for Humanity of Minnesota (Habitat Minnesota).
“We are excited to expand our retail footprint to six locations in Minnesota and our first in the southern region of the state,” said Green Thumb Founder and Chief Executive Officer Ben Kovler. “Along with this opening, we are extending our First Day Profits program to another state, allowing us to make an impact in the community with each new store. We are grateful for the opportunity to partner with Habitat Minnesota, who is doing the important work of bringing about systemic change, so all people have a safe, stable and affordable home.”
Habitat Minnesota brings people together to build homes, community and hope. The statewide support organization provides resources to 25 Minnesota affiliates to advance their work to create and preserve affordable homeownership. Habitat Minnesota offers a range of programs, including resource development, advocacy, training, and networking.
“Habitat’s work is possible because of strong community partnerships and we’re thankful for partners who understand the importance of this work statewide, like Green Thumb. Every community in Minnesota has an affordable housing shortage with 1 in 9 households paying more than they can afford on housing. This generous donation will support Habitat’s pursuit in advancing equity in affordable homeownership so more Minnesota families can affordably own a home. We appreciate Green Thumb’s partnership and their commitment to supporting the community,” said Cristen Incitti, CEO of Habitat for Humanity of Minnesota.
In addition to RISE Mankato, the Company has five other retail locations throughout the state, including: Eagan, Hibbing, St. Cloud, St. Paul and Willmar. Formerly known as LeafLine, each store was rebranded to RISE earlier this month. Profits from the first day of sales as newly branded RISE stores will also be donated to Habitat Minnesota. To celebrate the rebrand and welcome patients to the RISE experience, RISE will host a patient appreciation event on April 20, 2022, at each of its Minnesota retail locations. Representatives from the Company will be available to answer questions about Minnesota’s medical cannabis program, as well as assist with registering new patients. Discounts, giveaways and educational material will also be available for patients.
RISE Mankato is located at 1400 Madison Avenue East in Mankato. Regular hours are Monday through Saturday from 9 a.m. to 7 p.m. and Sunday from 10 a.m. to 5 p.m. Visit www.risecannabis.com/mn for more information.
About Green Thumb Industries:
Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves. Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles and RYTHM. The company also owns and operates rapidly growing national retail cannabis stores called RISE. Headquartered in Chicago, Illinois, Green Thumb has 17 manufacturing facilities, 77 open retail locations and operations across 15 U.S. markets. Established in 2014, Green Thumb employs approximately 3,800 people and serves millions of patients and customers each year. The company was named to Crain’s Fast 50 list in 2021 and a Best Workplace by MG Retailer magazine in 2018, 2019 and 2021. More information is available at www.GTIgrows.com.
I am still holding and hoping.
They need to excite more on the top line.
Hopefully it's a gang-buster surprise.
INDIVA TO REPORT FOURTH QUARTER AND FULL YEAR RESULTS PRE-MARKET ON TUESDAY APRIL 26, 2022
LONDON, Ontario – APRIL 7, 2022: Indiva Limited (the “Company” or “Indiva”) (TSXV:NDVA) (OTCQX:NDVAF), the leading Canadian producer of cannabis edibles and other cannabis products, announced today that it will report its annual results for the period ended December 31, 2021, pre-market on Tuesday, April 26, 2022.
CONFERENCE CALL – Tuesday, April 26, 2022 at 8:30 am EST:
The Company will host a telephone conference call to discuss its results on Tuesday, April 26, 2022 at 8:30 a.m. (EST). Interested participants may join by dialing 416-764-8658 or 1-888-886-7786. The conference ID number is 17137881.
A recording of the conference call will be available for replay following the call. To access the recording please dial 416-764-8691 or 1-877-674-6060. The replay ID is 137881#. The recording will remain available until Thursday, May 26th, 2022.
ABOUT INDIVA
Indiva sets the standard for quality and innovation in cannabis. As a Canadian licensed producer, Indiva produces and distributes award-winning cannabis products including Grön™ Pips and Pearls, Bhang® Chocolate, Wana™ Sour Gummies, Slow Ride Bakery Cookies, Jewels Cannabis Tarts, Ruby® Cannabis Sugar, Sapphire™ Cannabis Salt, as well as capsules, pre-rolls, and premium flower under the INDIVA and Artisan Batch brands. Click here to connect with Indiva on LinkedIn, Instagram, Twitter and Facebook, and here to find more information on the Company and its products.
INVESTOR CONTACT
Anthony Simone
Phone: 416-881-5154
Email: ir@indiva.com
Tilray Brands, Inc. Reports Third Quarter Fiscal Year 2022 Financial Results
April 6, 2022 at 7:00 AM EDT
https://finance.yahoo.com/quote/TLRY?p=TLRY&.tsrc=fin-srch
Profitable Quarter Includes Net Income of $52.5 Million and Adjusted EBITDA of $10.1 Million; 12th Consecutive Quarter of Positive Adjusted EBITDA
Net Revenue Increased 23% to $152 Million; Gross Profit Increased 31% to $39.8 Million from the Prior Year Quarter
Medical Market Share Leader in Europe and #1 Leadership Position in Germany with Revenue Growth of Over 4,000%
Maintained #1 Leading Marketing Share in Canada
Achieved $76 Million in Cost Synergies to Date; On-Track to Exceed Original Plan of $80 Million Ahead of Schedule and to Generate Additional $20 Million of Synergies in Fiscal 2023
LEAMINGTON, Ontario and NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today reported financial results for the third fiscal quarter ended February 28, 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Irwin D. Simon, Tilray’s Chairman and Chief Executive Officer, stated, “Our third quarter results reflect progress and momentum across all of our key business segments and geographies, setting the stage to achieve our target for $4B in revenue by the end of fiscal 2024. Tilray Medical – which now operates under a cohesive strategy and mission – has a near 20% share in Germany, providing clear benefits in its own right as well as a first-mover advantage that we will leverage as Germany and the EU move towards broader adult-use and medical use legalization. In Canada, we maintained our leading market share position amid intense competition – and believe that our strong capital position, operational excellence and pricing and marketing adjustments will work in concert to help ensure we reclaim share in the coming quarters. This effort will gain further support from the fundamental appeal of our brands and product innovation which, as stores continue re-opening, will resonate powerfully with consumers. In the U.S., our SweetWater Brewing, Breckenridge Distillery, and Manitoba Harvest businesses are profitable, growing and emerging as nationwide, iconic brands with loyal followings that will be home to THC-based products upon U.S. federal legalization.”
Mr. Simon continued, “We also continued sourcing and executing strategic and shareholder-friendly transactions that provide value with notable upside. Our most recent example is the proposed agreement to purchase the HEXO senior secured convertible notes, which provides a path for meaningful future equity ownership of HEXO as it executes on its transformation. The proposed HEXO transaction is also expected to facilitate complementary commercial and product innovation and drive production and operating efficiencies. As the global economy re-opens, we are confident that the global cannabis powerhouse at the heart of the Tilray Brands’ value proposition will deliver sustained and tangible shareholder value.”
Financial Highlights – Third Quarter Fiscal 2022
Net revenue increased 23% to $152 million during the third quarter from $124 million in the prior year quarter. The increase was driven by 32% growth in cannabis revenue to $55 million, 64% growth in beverage alcohol revenue of $20 million and wellness revenue of $15 million.
Gross profit increased 31% to $40 million from $30 million in the prior year quarter. Gross margin increased to 26% from 25% in the prior year quarter.
Significant growth in international cannabis with revenue up over 4,000% from the prior year quarter, and 37% increase in revenue in EMEA when compared to the previous quarter
Maintained #1 leadership position in Canada1 with 10.2% cannabis market share driven by Tilray’s comprehensive portfolio of adult-use brands, and growth in pre-roll and vape product categories.
Cost synergies from Aphria-Tilray combination of $76 million achieved on a run-rate basis to date. Expect to reach $80 million synergy target by May 31, 2022, five months ahead of schedule and to generate an additional $20 million in synergies in fiscal 2023.
Distribution revenue decreased 11% to $63 million during the third quarter from $70 million in the prior year quarter. The decrease was driven by the impact of changes in the exchange rate between the Euro and USD, which led to a $7 million reduction.
1 Based on Hifyre retail data.
Strategic Growth Actions
On April 6, 2022 – Manitoba Harvest announced an exclusive partnership with Whole Foods Market launching the brand’s Hemp+ Matcha and Supergreens powders exclusively at Whole Foods across North America.
On April 5, 2022 – The Brewers Association announced that SweetWater Brewing Co. is now the 10th largest craft brewer in the U.S.
On April 5, 2022 – Tilray Brands announced the launch of Solei Bites, the first THC edible available in Quebec, the 2nd largest market in Canada.
On March 24, 2022 – Solei, Tilray Brands’ best-selling Canadian wellness brand, announced the launch of Renew Moonlight, CBN vape pen for nighttime use.
On March 17, 2022 – Tilray Medical launched the first medical cannabis oil products in Malta.
On March 8, 2022 – Good Supply, Tilray Brands’ best-selling Canadian cannabis brand, announced the launch of Hash Bats, its new fastest growing infused pre-rolls.
On March 3, 2022 – Tilray Brands announced a proposed strategic alliance with Hexo Corp. to bring together Canada’s top two cannabis market share leaders to strengthen operational efficiencies and product innovation to benefit consumers, shareholders, and the cannabis industry.
On March 2, 2022 – Manitoba Harvest announced its new lineup of superfood products.
On February 22, 2022 – SweetWater Brewing Company launched across Oregon and Washington, marking the brand’s expansion into their 39th and 40th states.
On February 17, 2022 – Tilray Medical announced its first shipment of medical cannabis products to Malta.
On February 10, 2022 – Breckenridge Distillery launched its second (sold-out) series of ‘Super’ Sexy Motor Oil, a limited-edition Bourbon aged in beer barrels for over a year.
On February 9, 2022 – SweetWater Brewing Company announced its West Coast expansion into California and a partnership with the largest beer distributor in the U.S.
On February 8, 2022 – Tilray Brands launched Tilray Medical, a new comprehensive global division focused on international medical cannabis advocacy and a portfolio of EU GMP-certified medical brands and products.
On January 25, 2022 – Tilray Brands announced an expanded medical cannabis product offering in Australia and the launch of a new online medical cannabis education platform for healthcare professionals in Australia and New Zealand.
On January 20, 2022 – Manitoba Harvest introduced new hemp recipes compatible with Vegan, Keto, Paleo, and Gluten-Free Diets.
On January 10, 2022 – Tilray announced a new parent name, Tilray Brands, Inc., reflecting the Company’s evolution from a Canadian LP to a global consumer packaged goods company powerhouse with a market leading portfolio of cannabis lifestyle and CPG brands.
On December 21, 2021 – SweetWater Brewing Company acquired award-winning craft-beer brands, Alpine Beer and Green Flash Brewing.
On December 8, 2021, Tilray acquired Breckenridge Distillery, strengthening its strategic position in the U.S.
On December 2, 2021, Manitoba Harvest introduced Hemp Hearts health hacks for the holidays.
Growth and High Potential Across Key Markets
#1 Market Leading Position in Germany and Poised to Accelerate Strategic Growth Initiatives Upon Adult-Use Legalization – Today, Germany remains the largest medical cannabis market in Europe and is expected to also be one of the largest adult use markets as well upon legalization. We are already the leader in medical cannabis within Germany with a market share of approximately 20% with our whole flower, extracts and Dronabinol products and, this, together with our investments in infrastructure, brands and people, positions us exceptionally well for adult-use cannabis legalization.
Strategic Expansion Across the EU – Tilray Brands’ success across the EU, a powerful growth market worth potentially $1 billion for the Company, is backed by its two state-of-the-art cultivation facilities in Portugal and Germany that provide EU GMP certified pharmaceutical-grade medical cannabis across the region. This unparalleled production capability coupled with Tilray Brands’ sales arrangements through major distribution channels in Germany, the UK, and other key markets, coupled with the strong relationships with local governments and the trust of our patients, gives Tilray Brands the ability to drive accelerated growth.
#1 Leading Cannabis Market Share in Canada – Amid an intensely competitive and over-saturated market, Tilray Brands remains the market leader in the CAD$4.26 billion Canadian cannabis market, driven by a portfolio of carefully curated brands across all consumer segments; medical, wellness, innovative cannabis 2.0 products across concentrates, edibles, and drinks; processing capacity; and distribution. In order to address the saturated marketplace, Tilray Brands has implemented strategic price adjustments, expanded distribution through its coast-to-coast agreement with Rose Life Sciences and Great North Distributors, and increased our focus on and accelerated product innovation. Proposed alliance with Hexo Corp. (Nasdaq: HEXO) (TSX: HEXO) would bring together Canada’s top two cannabis market share leaders to strengthen operational efficiencies and product innovation to benefit consumers, shareholders, and the cannabis industry.
A Leading U.S. CPG Platform with Operational Strength, Leadership Expertise, and Optionality to be Immediately Leveraged for Cannabis Products Upon Federal Legalization - In the U.S., Tilray Brands’ operating businesses include SweetWater Brewing Company, the 11th largest craft brewer in the nation and leading lifestyle brand, Breckenridge Distillery, and Manitoba Harvest, a pioneer in hemp, CBD and wellness products. Together, they generate approximately $100 million in revenue and are EBITDA and cash flow positive and will expand in the near term into CBD adjacencies and THC-based products upon legalization. Further, the Company continues to build its U.S. platform, including through its prior acquisition of a majority of the outstanding senior secured convertible notes of MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) – which marked a critical step towards delivering on its objective of leading the U.S. cannabis market upon federal legalization.
Live Conference Call and Audio Webcast
Tilray Brands will host a live conference call and audio webcast to discuss these results today at 8:30 am Eastern Time, details of which are provided below.
Call-in Number: (877) 407-0792 from Canada and the U.S. or (201) 689-8263 from international locations. Please dial in at least 10 minutes prior to the start time.
A telephone replay will be available approximately two hours after the call concludes through April 22, 2022. To access the recording dial (844)-512-2921 from Canada and the U.S. or (412) 317-6671 from international locations and use the passcode 13728025.
There will be a simultaneous, live webcast available on the Investors section of Tilray Brands’ website at www.tilray.com. The webcast will also be archived. Additionally, Tilray's third quarter earnings call will be syndicated live to retail investors on the Public.com app.
About Tilray Brands
Tilray Brands, Inc. (Nasdaq | TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body, and soul while invoking wellbeing. Patients and consumers trust Tilray Brands to deliver a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray Brands’ unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we open a world of wellbeing, visit www.Tilray.com.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company’s ability to become the world's leading cannabis-focused consumer branded company; the Company’s ability to achieve market share and revenue growth in particular markets, including in Canada, the U.S. and the EU; our ability to achieve $4B in revenue by the end of fiscal 2024 and projected cost savings; and the likelihood and timing of any cannabis legislation in the U.S., Germany and other jurisdictions. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Use of Non-U.S. GAAP Financial Measures
This press release and the accompanying tables include non-GAAP financial measures, including adjusted gross margin, Adjusted EBITDA and adjusted free cash flow. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company's operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company's Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.
Adjusted EBITDA is calculated as net income (loss) before finance expense, net; non-operating expense (income), net; amortization; stock-based compensation; facility start-up and closure costs; inventory valuation adjustment; lease expense; and transaction costs. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Gross margin, excluding inventory valuation adjustments, is calculated as revenue less cost of sales adjusted to add back inventory valuation adjustments and amortization of inventory step-up, divided by revenue. A reconciliation of Gross margin, excluding inventory valuation adjustments, to gross margin, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Free cash flow is comprised of two GAAP measures deducted from each other which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets. Adjusted free cash flow removes the cash impact of acquisitions from free cash flow. A reconciliation of net cash flow provided by (used in) operating activities to free cash flow and to adjusted cash flows, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release.
For further information:
Media: Berrin Noorata, news@tilray.com
Investors: Raphael Gross, +1-203-682-8253, Raphael.Gross@icrinc.com
Sen. Lindsey Graham ‘open to’ medicinal marijuana as cannabis bill heads to senate
https://www.live5news.com/2022/04/01/sen-lindsey-graham-open-medicinal-marijuana-cannabis-bill-heads-senate/?fbclid=IwAR3OU66G5Pjon8ozlDEwMovR5jL2PbEMCHm3vX1VpHQYKKliYyhSser9Cl4
Sen. Lindsey Graham ‘open to’ medicinal marijuana as cannabis bill heads to senate
https://www.live5news.com/2022/04/01/sen-lindsey-graham-open-medicinal-marijuana-cannabis-bill-heads-senate/?fbclid=IwAR3OU66G5Pjon8ozlDEwMovR5jL2PbEMCHm3vX1VpHQYKKliYyhSser9Cl4
Been a long time since I've been here.
Green Thumb Industries Announces Conference Participation for April 2022
MARCH 31, 2022
CHICAGO and VANCOUVER, British Columbia, March 31, 2022 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (“Green Thumb”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE dispensaries, today announced its executive team will participate in the following conferences in April 2022:
BTIG Global Virtual Cannabis Conference, April 6 – April 7, 2022: Management will participate in one-on-one meetings.
2 nd Annual Cantor Virtual Cannabis Conference, April 12 – April 14, 2022: Management will participate in one-on-one meetings.
About Green Thumb Industries:
Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves. Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles and RYTHM. The company also owns and operates rapidly growing national retail cannabis stores called RISE. Headquartered in Chicago, Illinois, Green Thumb has 17 manufacturing facilities, 76 open retail locations and operations across 15 U.S. markets. Established in 2014, Green Thumb employs approximately 3,800 people and serves millions of patients and customers each year. The company was named to Crain’s Fast 50 list in 2021 and a Best Workplace by MG Retailer magazine in 2018, 2019 and 2021. More information is available at www.GTIgrows.com.
Thanks. Interesting. Does anyone else know about it? Volume(Heavy Day)
Today's volume of 11,320 shares is on pace to be much greater than ODYY's 10-day average volume of 27,916 shares.
April 01, 2022 10:05am ET
Odyssey Group International Announces Formation of Military Advisory Board and Welcomes Prestigious Members to Assist with Concussion Drug Development
Irvine, CA, March 31, 2022 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced the formation of its Military Advisory Board with the appointment of prestigious leaders in the field. Garnering experience and insight from these leaders in our military service branches will provide critical insight to traumatic brain injuries and the effects it has on those who suffer. Odyssey’s drug candidate, PRV-002 is intended to treat concussion and is currently in a phase 1 clinical trial. The initial members of the Military Advisory Board are:
James “Jim” Linder: Major General USA (r) Former Chief of Staff USSOCOM
“We have lived the consequences of TBI on the battlefield. Treatment at the point of injury and beyond is a challenge we must passionately and aggressively pursue.”
Francis Beaudette: Commanding General US Army Special Operations Command (r)
“Leaders at all levels have a moral and professional obligation to do everything possible to ensure and protect the comprehensive brain health of their Soldiers. It matters now, and will matter long after their service commitment to the Nation is complete. These responsibilities can only be fully accomplished through an active offense. The era of passive defense, or just simply hoping for the best, is long gone. Preparation and timely and accurate response are critical, now more than ever.”
Paul Toolan: Lieutenant Colonel (r)
“As I spend more and more time with retired and separated service members, I continue to be troubled by how many of them are struggling with neurological/cognitive issues on a spectrum from mild to severe. Having an opportunity to advocate for a treatment that could prevent these outcomes and improve the lives of the people who preserve our way of life, is an honor and a privilege.”
According to the CDC, millions of concussions occur each year in the United States and especially in the military.
“We are honored to have such distinguished and passionate leaders in our military join us in this much needed effort to find a viable treatment for brain injury,” commented Michael Redmond, CEO of Odyssey Group International.
Founding Members of the Military Advisory Board:
James Linder: Jim Linder is a recognized leader in the world of Special Operations and Intelligence organizations as a high performing and skilled strategist. A US General Officer with over three decades of direct command leadership around the globe.
Originally from South Carolina, Jim graduated from Clemson University as a Distinguished Military Graduate. His service has taken him to over 71 countries across Europe, into South East Asia, throughout Africa and the Middle East, and Central and South America.
As a General Officer, he created new cutting-edge capabilities and accelerated the growth of highly skilled Afghan Special Forces. He also led and directed all US special operations across the African continent, while interacting with US interagency and African leaders to achieve US national security goals. He adeptly applied new ideas as commandant of the Army’s premier Center of Excellence for selecting and training Special Operations Forces, and was the commander of all US and NATO special operations forces in combat in Afghanistan during a critical period of transition. Most recently, he achieved value-driven results managing a complex and agile organization of 80k persons with a $13.4B government operating budget as the Chief of Staff for US Special Operations Command.
Major General (retired) Linder is currently the President of Tenax Aerospace and has master’s degrees in International Relations from Webster University and also National Security and Strategic Studies from the US Naval War College.
Francis Beaudette: Over the course of his 32-year career in Army and Joint assignments, the majority of it as a Green Beret, Francis “Fran” M. Beaudette served with high performing organizations at varying levels, from a 12-man Special Forces ‘A-team’ to the 36,000-Soldier and Civilian US Army Special Operations Command.
His recent assignments were Deputy Commanding General of the 1st Armored Division, Assistant Commanding General of JSOC, CG of 1st Special Forces Command and Commanding General of the US Army Special Operations Command.
His operational assignments, totaling six years of deployed time, include the first Gulf War; comprehensive Africa experience to include noncombatant evacuation operations in Sierra Leone and the Congo; multiple peacekeeping operations in Kosovo; numerous deployments in Iraq, Afghanistan, the Philippines and Jordan, all during eras of war, turmoil or crisis.
Fran was a distinguished academic and military graduate from the Citadel and holds a MA in Military Arts and Science from the US Army Command & General Staff College and a MS in Strategic Studies from the US Army War College.
Paul Toolan : Lieutenant Colonel (LTC) Paul Toolan joined the Army as a Private in 1986. Over the course of more than three decades in uniform, he has risen through the ranks and completed every elite school in the US Army. He is a Special Forces Airborne Ranger and started his Special Forces career as a Detachment Commander in 3rd Special Forces Group at Fort Bragg. He has held nearly a dozen leadership positions in multiple Special Forces Groups, including Detachment Commander, Company Executive Officer, Battalion Operations Officer, Support Company Commander, Company Commander, Group Operations Officer, Group Executive Officer, Battalion Commander, Chief of the Special Forces Training Division, and the Director of Operations at 1st Special Forces Command. He has worked at the National Counter-Terrorism Center as a Special Forces advisor and worked as a Special Forces consultant in the United States Army Special Operations Commander’s Initiatives Group. He last duty assignment was the Deputy Commander of the 1st Special Warfare Training Group at Fort Bragg, North Carolina, where Green Berets are assessed, selected and trained.
Since retiring from military service, Paul has dedicated himself to helping Special Operators address the effects of life in Special Operations such as post-traumatic stress (PTS), traumatic brain injury (TBI) and Operator Syndrome (overstimulated sympathetic nervous system) by facilitating access to treatment innovations.
Having served for many decades in leadership roles, the members of this Board have a passion for helping active military personnel and our Veterans. They recognize the unique medical conditions they deal with and how important it is that they receive specialty care. Concussions have been linked to the increased incidence of PTSD, early-stage dementia and suicidal ideation. Odyssey is developing the first pharmaceutical to treat concussion in the acute phase of injury. A field deliverable intranasal device filled with their drug, PRV-002 can be kept in the medic’s bag or the soldier’s pocket for “buddy” aid immediately following a concussion. Reducing inflammation of the brain early on can significantly improve outcomes and return our soldiers back to action faster and safer.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC Pink: ODYY ) is focused on developing products in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful solutions to unmet medical needs. The Company is focused on technologies that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1 .
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. PRV-002 is currently in a Phase 1 clinical trial.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
The Street's vote on Trulieve's ER is pretty hum-drum--->>>Volume(Heavy Day) Today's volume of 224,094 shares is on pace to be much greater than TCNNF's 10-day average volume of 268,671 shares.
March 30, 2022 11:56am ET
Price $20.96 / Day's Change 0.26 (1.26%)
I'm not sure how to read GTI's sympathetic PPS rise on light trading?
Volume(Light) Today's volume of 172,333 shares is on pace to be much lighter than GTBIF's 10-day average volume of 662,327 shares.
March 30, 2022 11:59am ET
Price $17.86 / Day's Change 0.4435 (2.55%)
CRESCO is almost unchanged.
The Street hates the bought deal--->>>Volume(Heavy Day) Today's volume of 764,405 shares is on pace to be much greater than VLNS's 10-day average volume of 87,899 shares.
March 30, 2022 11:52am ET
Price $1.80 / Day's Change -0.53 (-22.75%)
It took the PPS a long time to get support. In minutes that all vanished.
Valens announces C$28.1M bought deal offering of units
Tilray Brands to Announce Third Quarter Fiscal 2022 Financial Results on April 6, 2022
March 30, 2022 at 7:07 AM EDT
https://ir.tilray.com/news-releases/news-release-details/tilray-brands-announce-third-quarter-fiscal-2022-financial
LEAMINGTON, Ontario, March 30, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (Nasdaq | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that the Company will release financial results for its third quarter fiscal 2022 ended February 28, 2022 before financial markets open on April 6, 2022.
Tilray executives will host a live conference call and audio webcast to discuss these results at 8:30 am Eastern Time, details of which are provided below.
Live Conference Call and Audio Webcast:
Date/Time: Wednesday, April 6, 2022 at 8:30 am Eastern Time.
Call-in Number: (877) 407-0792 from Canada and the U.S. or (201) 689-8263 from international locations. Please dial in at least 10 minutes prior to the start time.
A telephone replay will be available approximately two hours after the call concludes through April 22, 2022. To access the recording dial (844)-512-2921 from Canada and the U.S. or (412) 317-6671 from international locations and use the passcode 13728025.
There will be a simultaneous, live webcast available on the Investors section of Tilray’s website at www.tilray.com. The webcast will also be archived. Additionally, Tilray's third quarter earnings call will be syndicated live to retail investors on the Public.com app.
Tilray shareholders will be able to submit and upvote questions for the upcoming conference call to the executive team via shareholder Q&A platform Say Technologies.
To submit questions ahead of the conference call, please visit the Say platform (https://app.saytechnologies.com/tilray-2022-q3/) Tilray shareholders and brokers with Say can participate directly in their investing app or broker website. The Q&A platform for Tilray’s upcoming conference call on April 6, 2022 will remain open until 24 hours beforehand.
About Tilray Brands
Tilray Brands, Inc. (Nasdaq | TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body, and soul while invoking wellbeing. Patients and consumers trust Tilray Brands to deliver a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray Brands’ unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we open a world of wellbeing, visit www.Tilray.com.
Contacts
For media inquiries, please contact:
Berrin Noorata
news@tilray.com
For investor inquiries, please contact:
Raphael Gross 203-682-8253
Raphael.Gross@icrinc.com
Digestion of acquisitions never occurs overnight. Giant Fortune 500 companies have had indigestion for years.
BUD's takeover of Miller is a perfect example. It's not paying dividends.
CVS's takeover of Aetna took years to completely swallow. It is paying dividends.
We'll have to wait and see about Trulieve's big bite of the apple with Harvest.
As competition increases and legalization wanes, we wait.
Green Thumb Industries to Hold First Quarter 2022 Earnings Conference Call on May 4, 2022
MARCH 30, 2022
CHICAGO and VANCOUVER, British Columbia, March 30, 2022 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RYTHM, Dogwalkers and incredibles branded cannabis products, today announced it will hold a conference call on Wednesday, May 4, 2022, at 5:00 p.m. ET following the release of its first quarter 2022 financial results.
The earnings conference call may be accessed by dialing 844-883-3895 (Toll-Free) or 412-317-5797 (International). Investors may pre-register for the call by navigating to
https://dpregister.com/sreg/10165081/f21bb7f3d8. A live audio webcast of the call will also be available on the Investor Relations section of Green Thumb’s website at https://investors.gtigrows.com and will be archived for replay.
About Green Thumb Industries
Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves. Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles and RYTHM. The company also owns and operates rapidly growing national retail cannabis stores called RISE. Headquartered in Chicago, Illinois, Green Thumb has 17 manufacturing facilities, 76 open retail locations and operations across 15 U.S. markets. Established in 2014, Green Thumb employs approximately 3,800 people and serves millions of patients and customers each year. The company was named to Crain’s Fast 50 list in 2021 and a Best Workplace by MG Retailer magazine in 2018, 2019 and 2021. More information is available at www.GTIgrows.com.
CVS Health and Fresno housing collaborate to address affordable housing crisis and provide healthy homes in Fresno County
A rendered graphic of The Arthur @ Blackstone affordable housing complex in Fresno, California.
https://www.cvshealth.com/news-and-insights/press-releases/cvs-health-and-fresno-housing-collaborate-to-address-affordable
WOONSOCKET, R.I. — CVS Health and Fresno Housing have collaborated to build new affordable housing in Fresno, California. Through Red Stone Equity Partners, CVS Health will invest an estimated $18.4 million into the Arthur @ Blackstone, a new Fresno Housing development planning to break ground this spring.
Twenty of the units at the Arthur @ Blackstone will be reserved for special needs tenants, specifically transition age youth considered to be chronically homeless, homeless, or at-risk of becoming chronically homeless. This includes youth who are aging out of the foster care system, transitioning from institutions, and youth with a history of involvement in the justice system. The remaining units will target low-income families.
In addition, residents will benefit from comprehensive case management and full wrap around supportive services coordinated by the Fresno County Department of Behavioral Health and various contracted service providers.
The Arthur @ Blackstone is part of CVS Health’s commitment to addressing housing insecurities in the Fresno community and is one of three housing investments CVS Health has made with Fresno Housing over the past three years. Through investment funds sponsored by Red Stone Equity Partners, in 2019, CVS Health made a $4.6 million investment in Villages at Paragon and in 2020, announced it was investing $2.1 million in the Villages at Broadway.
“To make a meaningful impact, we need to address social determinants of health at the local level and be intentional with our approach,” said Jeff Hermosillo, California Market President, Aetna, a CVS Health company. “We’re committed to investing in the Fresno community and meeting the needs of individuals and families by providing them with resources that enable equal opportunity for achieving good health.”
This investment will continue to deepen the successful collaboration between Fresno Housing and CVS Health to reduce health disparities and advance health equity through quality, affordable housing. The Arthur @ Blackstone will consist of 41 housing units near Manchester Center in Fresno and will include a space where supportive services will be provided that aim to improve health outcomes for the residents.
“We know that when families have access to affordable housing, they are better able to improve their physical, mental, and emotional health. That’s why our partnership with CVS Health is exciting and innovative for the families we serve in our community. We are honored to be selected by CVS Health again to further our mission to provide affordable, healthy housing throughout Fresno County,” said Tyrone Roderick Williams, Chief Executive Officer, Fresno Housing.
Fresno Housing has been integrating the worlds of health and housing for the past 20 years by providing affordable housing and supportive services for over 4,000 families in Fresno County.
The investment in Arthur @ Blackstone builds on CVS Health’s commitment to the Fresno community. Earlier this year, CVS Health introduced its new Health Zones initiative to Fresno. The initiative provides concentrated local investments to reduce health disparities and advance health equity in underserved communities across the country. In Fresno, CVS Health is working with Fresno Economic Opportunities Commission, Clinica Sierra Vista, and the Central California Food Bank, to help improve health outcomes and build healthier communities in Fresno by addressing social determinants of health, including housing, education, access to food, labor, transportation, and health care access.
As part of CVS Health’s overall commitment to advance health equity in America, it invested $185 million in affordable housing nationwide in 2021 and $1.3 billion over the past 20 years, including $37.2 million in affordable housing in Fresno. Through these investments, CVS Health has been able to provide underserved communities with quality housing based on the unique needs of the population.
As part of CVS Health’s overall commitment to advance health equity in America, it invested $185 million in affordable housing nationwide in 2021 and $1.3 billion over the past 20 years, including $37.2 million in affordable housing in Fresno. Through these investments, CVS Health has been able to provide underserved communities with quality housing based on the unique needs of the population.
About CVS Health
CVS Health is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and approximately 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that’s managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Learn more at www.cvshealth.com.
Media contacts
Monica Prinzing
831-241-8294
PrinzingM@cvshealth.com
Brandi Borboa Johnson
559-908-7269
bjohnson@fresnohousing.org
Tuesday, March 29, 2022
Trulieve Caps Transformational Year with Record Fourth Quarter and Full Year 2021 Results
March 30, 2022 at 6:00 AM EDT
Record revenue of $938.4 million in 2021, up 80% year over year, and quarterly revenue of $305.3 million, up 36% sequentially
Industry leading U.S. retail network of 162 dispensaries, up 116% from 2020, supported by over 4.0 million square feet of cultivation and processing capacity, up 107% from 2020, as of March 30, 2022
TALLAHASSEE, Fla., March 30, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced its results for the quarter and full year ended December 31, 2021.
Results are reported in U.S. dollars unless otherwise indicated.
2021 Full Year Financial and Operational Highlights*
Revenue increased 80% year-over-year to $938.4 million in 2021.
Gross profit of $566.1 million and gross margin of 60.3% in 2021 compared to gross profit of $386.4 million and gross margin of 74.1% in 2020.
Adjusted gross profit of $621.4 million and adjusted gross margin of 66.2% in 2021 compared to adjusted gross profit of $389.9 million and adjusted gross margin of 74.8% in 2020.* The decline in adjusted gross margin is primarily attributable to strategic diversification into new lower margin markets and channels.
Net income of $18.0 million and adjusted net income of $123.4 million*, which excludes $105.4 million of non-recurring compensation, fair value of inventory step up, and transaction, acquisition and integration charges primarily associated with the Harvest Health & Recreation Inc. ("Harvest") acquisition.
Adjusted EBITDA of $384.6 million, or 41.0% of revenue in 2021 compared to adjusted EBITDA of $260.1 million, or 49.9% of revenue in 2020.*
Cash at year end of $234 million.
Raised $227 million in equity and $350 million in five year senior secured notes at 8% interest, representing industry leading terms for U.S. plant touching cannabis operators.
Welcomed two new members to the Board of Directors, which now includes four women representing half of the Board.
Closed seven total acquisitions valued at ~$1.5 billion in 2021 including Harvest and Keystone Shops. The Harvest acquisition closed in less than five months from the announcement, accelerating integration and optimization activities.
Added 84 dispensaries in 2021, increasing retail footprint by 112% to 159 retail locations nationwide at year end.
Added ~1.6 million square feet of cultivation and processing capacity through organic growth and acquisitions in 2021, increasing capacity by 89% to over 3.5 million square feet at year end.
Commenced cultivation and retail operations in Massachusetts and West Virginia and received a notice of intent to award a Class 1 production license in Georgia.
Exited 2021 with operations in 11 states, with 30% of our retail locations outside of the state of Florida.
*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
Q4 2021 Financial and Operational Highlights*
Revenue increased 81% in the fourth quarter compared to the fourth quarter of 2020 and 36% sequentially to $305.3 million.
Gross profit of $132.4 million and gross margin of 43.4% in the fourth quarter of 2021 compared to gross profit of $119.9 million and gross margin of 71.2% in the fourth quarter of 2020.
Adjusted gross profit of $180.6 million and adjusted gross margin of 59.1% in the fourth quarter of 2021 compared to adjusted gross profit of $121.7 million and adjusted gross margin of 72.2% in the fourth quarter of 2020.*
Net loss of $71.5 million and adjusted net income of $1.8 million*, which excludes $73.3 million of non-recurring fair value of inventory step up, and transaction, acquisition and integration charges primarily associated with the Harvest acquisition.
Adjusted EBITDA of $100.9 million, or 33.0% of revenue in the fourth quarter of 2021 compared to adjusted EBITDA of $81.4 million or 48.3% of revenue in the same period of the prior year.
Added 58 dispensaries in the fourth quarter including 49 acquired through Harvest and Purplemed, 9 opened in Florida, Pennsylvania, and West Virginia, and completed the relocation of two dispensaries in Florida.
Rebranded and reopened fourteen legacy Harvest dispensaries in Florida during October as required following the Harvest acquisition.
Released our inaugural ESG report, building upon the work done in our Sustainability Report in 2020.
*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
Recent Events
Closed second tranche of private placement of 8% senior secured notes due October 2026 totaling $75 million.
Opened 3 new dispensaries in Boca Raton and Riverview, Florida and Philadelphia, Pennsylvania.
Completed the rebranding to Trulieve of 22 affiliated and acquired retail locations in Maryland and Pennsylvania.
Currently operate 162 retail dispensaries and over 4.0 million square feet of cultivation and processing capacity in the United States.
Acquired 64K square feet of operational indoor cultivation capacity in Arizona.
Expanded or entered into new branded partnerships with Connected, El Blunto, Khalifa Kush, and Miami Mango.
Announced a partnership with Survivor's Ethan Zohn as a brand ambassador for Momenta branded products.
Launched nationwide Supplier Diversity Initiative.
Management Commentary
"2021 was a phenomenal year for Trulieve, full of monumental achievements, punctuated by the completion of the Harvest acquisition," said Kim Rivers, Trulieve CEO. "We delivered another record year while making substantive progress toward achieving our long-term goals."
Rivers continued, "Our team built upon our established track record of success, further expanding our distribution network through our hub strategy while setting the stage for continued growth. In 2022 we expect to deliver improved performance as our efforts to optimize assets and teams across our platform provide meaningful contributions to our results."
Financial Guidance
Trulieve is introducing 2022 guidance with expected revenue in the range of $1.3 billion to $1.4 billion and adjusted EBITDA* in the range of $450 million to $500 million. Based on our current forecasts, we expect to realize improved performance in the second half of 2022 relative to the first half of 2022.
Financial Highlights
https://investors.trulieve.com/news-releases/news-release-details/trulieve-caps-transformational-year-record-fourth-quarter-and
Trulieve Cannabis Non-GAAP EPS of $0.01 misses by $0.16, revenue of $305.3M misses by $0.57M
06:07 AM | Trulieve Cannabis Corp. (TCNNF) | By: Deepa Sarvaiya, SA News Editor
Trulieve Cannabis press release (OTCQX:TCNNF): Q4 Non-GAAP EPS of $0.01 misses by $0.16.
Revenue of $305.3M (+81.3% Y/Y) misses by $0.57M.
Adjusted EBITDA of $100.9 million, or 33.0% of revenue in the fourth quarter of 2021 compared to adjusted EBITDA of $81.4 million or 48.3% of revenue in the same period of the prior year.
Adjusted gross margin of 59.1%
Gross margin of 43.4%
MediPharm Labs Sets Date to Report Fourth Quarter and Full Year 2021 Financial Results
Tue, March 29, 2022, 7:00 AM·
4 min read
TORONTO, March 29, 2022 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three and twelve month period ended December 31, 2021 after markets close on Thursday, March 31, 2022.
MediPharm's executive management team will also host a conference call and audio webcast on Friday, April 1, 2022, at 8:30 a.m. eastern time to discuss the Company's financial results and outlook.
Audio Conference Call Dial in Details:
Toll-free number: +1 (888) 330-2454 / International number: +1 (236) 789-2714 / Conference ID: 4921762
Participants are asked to dial in approximately 15 minutes before the start of the call.
Audio Webcast:
An audio webcast will be available in the Events section of the MediPharm website https://www.medipharmlabs.com/investors or by visiting the following link here.
For those who are unable to participate on the live conference call or webcast, a replay will be available approximately one hour after completion of the call.
About MediPharm Labs Corp.
Founded in 2015, MediPharm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, API and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.
In 2021, MediPharm received a Drug Establishment Licence from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing Practices licence for the extraction of natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
I have no confidence in federal legalization efforts. I have confidence that The Street will need to reconcile GTI reaching revenues of $1.5B within two years.
GTI is a good buy.
They have a long way to go. I am still holding
Aleafia Health gains market share in adult use cannabis market, provides strong sales outlook
07:47 AM | Aleafia Health Inc. (ALEAF) | By: Khyathi Dalal, SA News Editor
Aleafia Health (OTCQX:ALEAF) indicated that it continues to expand market share by focusing on the highest revenue generating dried flower, pre-roll, and vape product categories.
It also changed business strategy to become a branded cannabis products provider, with branded cannabis representing 80% of total net revenue in 2021 compared to 33% in 2020.
In February, Aleafia Health achieved record 2.06% adult use market share in four major markets, advancing 33% from 1.54% in November 2021; market share in flower rose to 1.86% from 1.47%, pre-rolls rose to 2.62% from 2.09%, vapes rose to 2.18% from 0.92%, and oil rose to 4.01% from 2.68%.
Market share growth were hampered by temporary capacity limitations at the company's Grimsby greenhouse facility.
Besides receiving a $1M purchase order from Ontario for adult use products, it has secured purchase orders in 2022 YTD from Australia and Europe that exceed 2021 second half sales to international markets.
The company is targeting break-even adj. EBITDA profitability in 2H22.
Shares trading 5% down premarket.
Nothing much
MEDIA ALERT: BRAINCHIP DEMONSTRATES NEUROMORPHIC AI CAPABILITIES OF ITS AKIDA PLATFORM AT TINYML SUMMIT 2022
Laguna Hills, Calif. – March 23, 2022 – BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power neuromorphic AI chips and IP, is exhibiting the latest capabilities of its Akida™ neuromorphic technology in person at tinyML Summit 2022. TinyML Summit will feature technical progress and ecosystem development within the “tiny” machine learning industry to enable ultra-low power ML in edge applications.
tinyML Summit 2022
Date:
March 28-30, 2022
Location:
Hyatt Regency San Francisco Airport
1333 Bayshore Highway
Burlingame, CA 94010
Tiny ML is a growing field of ML technologies including hardware (dedicated integrated circuits), algorithms, and software capable of performing on-device data analytics at extremely low power to enable a range of always-on applications, primarily in battery-operated devices. Tiny ML is common in audio, visual, navigational, biometric, and medical devices as well as other commercial and industrial uses.
“BrainChip appreciates the opportunity to showcase our achievements in neuroprocessing at the edge that enable even lower-power, higher-performing AI in audio, vision, olfactory, lidar and other edge sensors,” said Kristofor Carlson, BrainChip’s Manager of Applied Research.
Kristofor Carlson will lead the company’s Poster sessions throughout the conference. Additionally, company representatives will be demonstrating the latest advancements of BrainChip’s neuromorphic computing solutions in the Exhibit space.
Those interested in speaking with BrainChip at tinyML Summit 2022 can contact sales@brainchipinc.com to schedule an appointment.
About tinyML Summit 2022
tinyML Summit 2022 allows attendees to take part in the sharing, learning, and celebrating tinyML. With ever more pervasive advances in technology and algorithms, tinyML is rapidly becoming a reality. The incredibly open and collaborative nature of ML technology allows this field to advance so quickly. From its inception in 2019, the tinyML community has grown tremendously and has benefited greatly by supporting one another. Through leveraging the collective knowledge of the community, the Summit presents attendees with the opportunity to learn new ideas and approaches to solve problems and become more effective and efficient.
About BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY)
BrainChip is a global technology company that is producing a groundbreaking neuromorphic processor that brings artificial intelligence to the edge in a way that is beyond the capabilities of other products. The chip is high performance, small, ultra-low power and enables a wide array of edge capabilities that include on-chip training, learning and inference. The event-based neural network processor is inspired by the spiking nature of the human brain and is implemented in an industry standard digital process. By mimicking brain processing BrainChip has pioneered a processing architecture, called Akida™, which is both scalable and flexible to address the requirements in edge devices. At the edge, sensor inputs are analyzed at the point of acquisition rather than through transmission via the cloud to a data center. Akida is designed to provide a complete ultra-low power and fast AI Edge Network for vision, audio, olfactory and smart transducer applications. The reduction in system latency provides faster response and a more power efficient system that can reduce the large carbon footprint of data centers.
Green Thumb Industries Continues Community Investment Initiatives with Donation to Olive-Harvey College in Chicago
MARCH 24, 2022
https://investors.gtigrows.com/investors/news-and-events/press-releases/press-release-details/2022/Green-Thumb-Industries-Continues-Community-Investment-Initiatives-with-Donation-to-Olive-Harvey-College-in-Chicago/default.aspx
CHICAGO and VANCOUVER, British Columbia, March 24, 2022 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE dispensaries, is expanding its partnership with Olive-Harvey College by donating $200,000 to support the school’s cannabis education program. The program provides training, scholarships, equipment, staffing and industry access to help create a more diverse workforce within the cannabis industry. Olive-Harvey is a community college on the southeast side of Chicago and is part of the City Colleges of Chicago.
The donation was made on behalf of Green Thumb’s Growing for Good social impact program and fulfills the Company’s Social Equity Inclusion plan requirement for Illinois’ early approval adult-use cultivation license holders. Green Thumb chose to partner with Olive-Harvey College, which has the only credit-approved cannabis training program in Chicago, to further the impact the school is making to prepare Black and Brown students for a career in cannabis while strengthening diversity in the industry??.
“Olive-Harvey College is doing the important work of building opportunity for Black and Brown students across Chicago by providing them with education, training and industry expertise, and we are thrilled to continue our partnership with them,” said Green Thumb Director of Social Impact Jai Kensey. “Giving back is at the core of Green Thumb and we believe it is our responsibility to reduce barriers to entry into the cannabis industry for those most impacted by the War on Drugs. We look forward to working alongside the team at Olive-Harvey to create a more equitable cannabis industry.”
Amanda Gettes, Executive Dean of Urban Agriculture at Olive-Harvey, said: “Green Thumb’s contribution will ensure the Cannabis Education program at Olive-Harvey College continues to thrive and provide training and industry access to a diverse workforce.”
Those interested in learning more about the Cannabis Education program should contact Olive-Harvey College directly. More information is available at www.ccc.edu. More information on Green Thumb’s Growing for Good social impact program is available at www.gtigrows.com/social-impact.
About Green Thumb Industries
Green Thumb Industries Inc. (“Green Thumb” or the “Company”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves. Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles and RYTHM. The company also owns and operates rapidly growing national retail cannabis stores called RISE. Headquartered in Chicago, Illinois, Green Thumb has 17 manufacturing facilities, 76 open retail locations and operations across 15 U.S. markets. Established in 2014, Green Thumb employs approximately 3,800 people and serves millions of patients and customers each year. The company was named to Crain’s Fast 50 list in 2021 and a Best Workplace by MG Retailer magazine in 2018, 2019 and 2021. More information is available at www.GTIgrows.com.